Merck & Co., Inc. 10-K — AI Bull & Bear Analysis

The 2025 10-K presents a company in a high-stakes race against time, balancing strong financial performance against systemic regulatory and financial risks. While the growth in net income and the successful launch of Winrevair provide a bullish signal, the underlying cash flow volatility and the scale of the debt-funded acquisition strategy suggest a more fragile foundation than the surface numbers imply. Ultimately, the investment case hinges on whether Merck can successfully diversify its revenue stream before the Keytruda patent cliff and IRA price caps take full effect. The company's ability to resolve the Halozyme patent dispute and advance its Phase 3 pipeline will be the deciding factors in whether it can maintain its status as a compounding growth engine or succumb to the pressures of its leveraged balance sheet.